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Background/Aims: Chronic hepatitis C virus (HCV) infections 
put patients at risk of serious liver disease and adversely 
affects patient quality of life (QoL). MOSAIC (International 
Multicenter Prospective Observational Study to Evaluate the 
Epidemiology, Humanistic and Economic Outcomes of Treat-
ment for Chronic Hepatitis C Virus) was a prospective, non-
interventional, international, multicenter study that aimed to 
describe the epidemiology of the infection, the impact of the 
infection on health-related QoL (HRQoL) and daily activities, 
and healthcare resource use related to HCV and treatment. 
Here, we present the results on HRQoL and daily activity 
impairment in consecutively enrolled South Korean patients 
treated with interferon (IFN)-containing regimens prospec-
tively followed for up to 48 weeks. Methods: General HRQoL, 
HCV-specific HRQoL, perceived health state, and work/
general activity impairments were measured using the Eu-
roQoL 5-dimension 5-level (EQ-5D-5L), HCV patient-reported 
outcomes (HCV-PRO), EQ-5D Visual Analog Scale, and Work 
Productivity and Activity Impairment questionnaires, respec-
tively. Results: Thirty-three of the 100 enrolled patients 
initiated IFN-based treatment, with an intended duration of 
24 weeks for 20 patients and 48 weeks for 12 patients; this 
information was missing for one patient. Fourteen patients 
(42.4%) prematurely withdrew. After treatment initiation, IFN-
treated patients showed a trend towards deterioration of 
both general (baseline: 0.87±0.103, week 4: 0.77±0.153) 
and HCV-specific (baseline: 76.2±19.5, week 4: 68.2±22.3) 
HRQoL. The scores recovered somewhat towards the end of 
treatment (EOT) (0.84±0.146 for EQ-5D-5L and 70.8±21.9 
for HCV-PRO). The perceived health state and work/general 
activity impairment displayed similar temporal patterns. Con-
clusions: Initiating IFN-based treatment prompted some de-
terioration in general and HCV-related HRQoL, accompanied 
by impaired daily activities and most work productivity mea-
sures; however, the HRQoL and productivity scores improved 
towards the EOT. HRQoL impairment upon treatment initia-
tion likely contributed to treatment discontinuation. (Gut Liver 
2020;14:368-376)
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INTRODUCTION
Chronic infection with the hepatitis C virus (HCV) may lead to 
the development of serious liver diseases, such as cirrhosis and 
hepatocellular carcinoma.1 Based on the natural history of the 
disease, it has been estimated that, over 20 to 30 years, up to 
20% of patients develop cirrhosis while 1% to 5% may develop 
hepatocellular carcinoma.1 Chronic HCV infection is also known 
to have a severe negative impact on the patient’s quality of life 
(QoL).2-4
The World Health Organization reports that 71 million people 
worldwide suffer from chronic hepatitis C and almost 400,000 
die from the disease every year.5 However, actual hepatitis C 
prevalence may be higher: according to a recent literature re-
view, global prevalence of HCV was estimated at 2.5%, equat-
ing to 177.5 million infected individuals.6 In South Korea, the 
prevalence of HCV is relatively low–it was estimated at 0.6% 
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to 1.1% according to a recent review.7 Between 2007 and 2011, 
approximately 60,000 patients per year were diagnosed with 
hepatitis C across the country.8 
HCV infection, particularly a chronic and progressive one, 
poses a substantial humanistic, clinical and economic burden 
both to those affected, and to the society as a whole. A retro-
spective observational study conducted in eight South Korean 
institutions revealed that, without antiviral treatment, disease 
progression rate was significantly higher than with treatment 
among both patients with chronic hepatitis C and those with 
compensated cirrhosis.9 However, in those whose disease had 
progressed to the decompensated cirrhosis stage, antiviral treat-
ment did not affect further disease progression.9 Hospitaliza-
tion and outpatient visit requirements increased with disease 
progression, as did medical costs: the median total medical cost 
per patient over the 2-year study period ranged from US$1,179 
for patients with chronic hepatitis C to US$8,255 in those with 
hepatocellular carcinoma.9
Antiviral treatment is crucial for preventing disease progres-
sion. The Korean Association for the Study of the Liver has 
published Practice Guidelines for Management of Hepatitis C,10 
providing comprehensive guidance for Korean physicians treat-
ing patients infected with HCV. The combination of pegylated 
interferon α (peg-IFN) and ribavirin (RBV) was the mainstay of 
chronic hepatitis C therapy in South Korea before direct-acting 
antivirals (DAAs) were approved.11 DAAs have produced a 
paradigm shift in the treatment of chronic hepatitis C in Korea, 
allowing up to 90% of treated patients to achieve a sustained 
virological response with minimal adverse events.10 Overall 
the Korean Association for the Study of the Liver guidelines 
recommend that treatment should be individualized, taking 
into account a number of factors, such as liver disease severity, 
probability of treatment success, risks of severe adverse effects, 
concomitant diseases, and patient preference.10
The MOSAIC (International Multicenter Prospective Obser-
vational Study to Evaluate the Epidemiology, Humanistic and 
Economic Outcomes of Treatment for Chronic Hepatitis C Virus) 
study was conducted to investigate the epidemiology of HCV 
and provide real-world data on the clinical, humanistic and eco-
nomic burden of HCV treatment. In this publication, we present 
the results from the Korean cohort enrolled in this study, focus-
ing on health-related QoL (HRQoL).
MATERIALS AND METHODS
1. Objectives
MOSAIC was a prospective, non-interventional, international, 
multicenter study. 20 countries including Canada, Russia, Po-
land, and etc. participated this MOSAIC trial. In South Korea, 
five sites conducted this study. The study comprised three phas-
es.
The objective of phase 1 (inclusion) was to describe the epi-
demiology of HCV infection in South Korea and characterize 
patients seeking care for HCV. Phases 2 (baseline) and 3 (follow-
up) aimed to: (1) determine how baseline HRQoL and any sub-
sequent HRQoL changes may affect completion of IFN-based 
treatment; (2) assess the impact of HCV and its treatment on 
work productivity and activities of daily living; and (3) estimate 
healthcare resource utilization associated with HCV treatment.
2. Study design
The study involved up to five visits: visit 1 in phase 1, visit 2 
in phase 2 and visits 3–5 in phase 3. Phase 1 included consecu-
tive patients with chronic HCV infection who were not under-
going treatment at study inclusion, regardless of HCV genotype, 
any prior treatment, comorbidities and adjuvant therapies. 
Demographic and clinical characteristics relevant to chronic 
hepatitis C were documented in this first study phase. Partici-
pating sites also took note of all patients eligible for inclusion in 
the study but who were not willing to participate; information 
on age range and the main reason for not participating was col-
lected for these patients.
The study ended with phase 1 for all patients except those 
who initiated an IFN-based treatment regimen within 12 weeks 
of the phase 1 visit, as these patients were included in phases 
2 and 3. In phase 2, patients started IFN-based treatment and 
filled out study questionnaires. Treating physicians provided in-
formation on general and HCV-related medical history and prior 
treatment based on patients’ medical records. Information col-
lected at visit 2 (at treatment initiation) served as baseline data 
for information collected in phase 3. Patients who did not initi-
ate IFN-based treatment within the 12-week time frame were 
not included. Patients were prospectively followed for up to 48 
weeks from the start of treatment (phase 3) over three follow-up 
visits: the first two at weeks 4 and 12 from visit 2, and the final 
visit at week 48 or end of treatment (EOT), whichever occurred 
first. At each visit, patients’ clinical status and HCV-related re-
source utilization were documented, and the patients filled out 
the study questionnaires listed in Table 1.12-15 
All treatment, procedures and diagnostic methods followed 
routine clinical practice. Treatment decisions were solely at the 
discretion of the treating physician, and all eligible study partic-
ipants received HCV treatments available on the market, includ-
ing peg-IFN with or without RBV, either as a single regimen or 
co-administered with a DAA (telaprevir or boceprevir).
The study was observational and data were collected from all 
participants, regardless of the precise treatment regimen they 
received. Informed consent was obtained from all participants 
included in the study. The study complied with the Ethical Prin-
ciples for Medical Research Involving Human Subjects outlined 
in the Helsinki Declaration in 1975 (revised in 2000) and was 
approved by Institutional Review Boards of the participating 
centers. 
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3. Statistical analysis
Descriptive statistics were calculated for patient and disease 
baseline characteristics, and for all QoL assessments. For the 
latter, five assessment time points are presented, that is, base-
line, week 4, week 12, EOT, and week 48. If QoL questionnaires 
were missing for week 4 or week 12, and the EOT questionnaire 
of the same patient fell within the time window for week 4 or 
week 12, the EOT data were also analyzed under that time point. 
Data in text are presented as mean±standard deviation.
RESULTS
1. Patient characteristics
As of the cutoff date (June 30, 2016), 155 Korean patients 
were recorded in the study database, of whom 55 chose not to 
participate in the study. As a result, a total of 100 Korean pa-
tients were enrolled in phase 1; 86 were treatment-naïve and 14 
were previously treated. Of these, 30 treatment-naïve and three 
treatment-experienced patients initiated IFN-based treatment 
and were included in phase 2 (see Fig. 1 for a flow diagram of 
study participants). The three treatment-experienced patients 
had previously been treated with peg-IFN+RBV (n=2) or other 
regimens (n=1), but discontinued therapy (n=2), or relapsed 
(n=1). Mean age of patients participating in phases 2 and 3 was 
54.5 years (range, 35 to 71 years) and the majority were female 
(n=19, 57.6%). The predominant HCV genotype was G2 (n=19, 
57.6%). With regard to liver fibrosis status, this was missing for 
eight patients (24.2%), and less than half of the patients (n=14, 
42.4%) had minimal or no liver fibrosis. Baseline and disease 
characteristics of patients included in phase 2 are shown in 
Table 2. 
2. Treatment
Of the 33 patients included in phases 2 and 3, the majority 
(26 patients [78.8%], including all three treatment-experienced 
ones) were treated with the combination of peg-IFN and RBV. 
Six patients (18.2%) were treated with the combination of stan-
dard IFN and RBV and one patient (3%) was treated with peg-
IFN alone, without the addition of RBV. The intended treatment 
duration was 24 weeks in 20 patients (60.6%) and 48 weeks in 
12 patients; information was missing for one patient. Nineteen 
patients (57.6%) completed treatment as planned and 14 (42.4%) 
withdrew prematurely (Fig. 1), of whom, four (28.6%) were lost 
to follow up or withdrew consent and 10 (71.4%) withdrew for 
other reasons. Among these 14 patients, two received IFN and 
RBV, 11 peg-IFN and RBV, and one peg-IFN alone.
It is worth highlighting that the EOT corresponds to when 
treatment was prematurely discontinued in some patients, and 
is not always equivalent to the completion of the full intended 
treatment period. However, as only five patients (15.2%) contin-
ued treatment until week 48, we focused the results presentation 
Table 1. Study Questionnaires
Questionnaire name Scope Scoring
EQ-5D-5L12,13 General QoL Possible index scores range between –0.109 and 1, with 
higher scores indicating better QoL.
Visual Analogue Scale Self-rated health state Scores range from 0 to 100, with higher scores indicating 
better QoL.
HCV-PRO14 Hepatitis C-specific QoL Scores range from 0 to 100, with higher scores indicating 
better QoL.
WPAI15 WPAI. The questionnaire produces four 
scores, each for a different aspect of 
work and activity impairment:
The four scores range from 0 to 100%, with higher per-
centages indicating more severely impaired productiv-
ity. Scores for absenteeism, presenteeism and total work 
productivity impairment were not recorded for patients 
who were not employed at the time of the assessment.
   Absenteeism Percentage of work time missed due to 
hepatitis C
   Presenteeism Percentage of impairment due to hepatitis 
C while working
   Total work productivity impairment Percentage of overall work impairment
   Total activity impairment Percentage of general (non-work) activity 
impairment due to hepatitis
EQ-5D-5L, EuroQoL 5-dimension 5-level; HCV-PRO, hepatitis C virus patient-reported outcomes; WPAI, Work Productivity and Activity Impair-
ment questionnaire; QoL, quality of life.
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on the change in QoL and productivity from baseline to the 
EOT, with week 48 data shown for information only.
Among 33 patients with enrolled phase 2 of this study, 22 
patients were achieved sustained viral response rate at 12 weeks 
(SVR12) after treatment (66.7%, 22/33). The SVR12 of patient 
of genotype 1 was 63.6% (7/11) and SVR12 of genotype 2 was 
68.2% (15/22) respectively.
3. Health-related QoL
After treatment initiation, IFN-treated patients showed a 
slight trend for deterioration of both general and HCV-specific 
HRQoL, measured using EuroQoL 5-dimension 5-level (EQ-5D-
5L) and HCV patient-reported outcomes (HCV-PRO), respec-
tively. All 33 patients filled in the EQ-5D-5L at baseline and 
the mean score was 0.87±0.103. Mean scores were substantially 
lower at weeks 4 and 12, but at the EOT they partially recov-
ered reaching on average 0.836±0.146 across the 23 patients 
who filled in the questionnaire (Fig. 2). In the four patients who 
continued treatment until week 48, the EQ-5D-5L score at week 
48 neared the baseline value, with a mean of 0.867±0.089. The 
mean decreases in EQ-5D-5L score from baseline to the EOT 
was 0.03±0.18 when all available data for the two time points 
were used. When only patients with available data for both time 
points (i.e., baseline and week 4, baseline and week 12, etc.) 
were included in the calculation, a similar temporal pattern was 
also observed, with scores decreasing noticeably from baseline 
in weeks 4 and 12 to recover somewhat at the EOT (data not 
shown).
As part of the EQ-5D-5L questionnaire, patients also marked 
their perceived health state on a visual analogue scale (VAS). 
When all available data was used, the mean health state rating 
at baseline was 78±13.5 (n=33), but, similar to the general EQ-
5D-5L score, it decreased after patients initiated treatment with 














Lost to follow-up/consent withdrawn (n=1)
Weeks 5 12
Discontinued for other reasons (n=5)
Weeks 13 24
Discontinued for other reasons (n=3)
Lost to follow-up/consent withdrawn (n=3)
Weeks 25 48
Discontinued for other reasons (n=2)

































Phase 2 and 3
Fig. 1. Flow diagram of study par-
ticipants. IFN, interferon.
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on average (n=23) (Fig. 3). 
Considering only patients with available data at both time 
points, there was a significant decrease in the EQ-5D VAS 
score from baseline to week 4 (n=28, 77.5 vs 67.7, respectively, 
p=0.003 two-sided paired t-test) and from baseline to week 12 
(n=26, 78.1 vs 70.6, respectively, p=0.006 two-sided paired t-
test). However, there was no statistically significant difference 
between EQ-5D VAS scores at baseline and at EOT (n=23, 77.2 
vs 75.4, p=0.621 two-sided paired t-test). These comparing re-
sult among the 22 patients who achieved SVR12 was same as 
well, except between week 12 and EOT. The EQ-5D VAS scores 
showed statistically significant increase at EOT compare to week 
12 (n=18, 73.3 vs 78.3, respectively, p=0.011 two-sided paired t-
test). 
In terms of HCV-specific QoL aspects measured using HCV-
PRO (Fig. 4), the mean baseline score among all 33 patients 
participating in the study was 76.2±19.5. Similar to the general 
QoL (EQ-5D-5L) scores, the average HCV-PRO score decreased 
at week 4. This decrease continued through week 12 but scores 
recovered partially at the EOT, reaching on average 70.8±21.9 
in the 23 patients who responded. A similar near-recovery of 
the HCV-PRO score was observed at week 48 in patients who 
continued treatment until that point (72.1±18.8, n=4). The 
mean decrease in HCV-PRO score from baseline to the EOT was 
5.40±29.32 when all available data for the two time points were 
used. Considering only patients with available data at both time 
points, the pattern of responses over time was similar (data not 
shown).
Korean patients treated with IFN also noted impairment in 
work productivity and general activities, as measured using the 
Work Productivity and Activity Impairment (WPAI) question-
naire (Table 3, Fig. 5). The results for the former measure were, 
Table 2. Baseline Patient and Disease Characteristics Stratified by 
Treatment Group
Patients in phase 2 Value (n=33)
Sex
   Male 14 (42.4)
   Female 19 (57.6)
Age, yr 54.5 (35–71)
Detailed liver fibrosis stage 
   (excluding cases with unknown status)
      Minimal or no fibrosis  14 (56.0)
      Portal fibrosis 2 (8.0)
      Bridging (or septal) fibrosis  3 (12.0)
      Cirrhosis  6 (24.0)
      Unknown  8 (32.0)
Hepatitis C virus genotype
      G1 11 (33.3)
      G2 19 (57.6)
      G3 3 (9.1)
Extrahepatic manifestations present 2 (6.1)
Data are presented number (%) or mean (range).
Fig. 2. EQ-5D-5L scores over the treatment period. 



































Fig. 3. Self-rated health state recorded on the EQ-5D VAS.










































Fig. 4. HCV-PRO scores over the treatment period.
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however, limited to patients who were employed at the time of 
the assessment (15 patients, at baseline; 12, at week 4; 10, at 
week 12; one, at week 48 and 10 at EOT). From a baseline aver-
age of 22.1%±29.4% across 14 patients, the estimated percent-
age of impairment due to hepatitis C while working (presentee-
ism) increased slightly (by 3.9%±40.9%) to reach 26.0%±28.4% 
among 10 respondents at the EOT. On the other hand, absentee-
ism (i.e., the percentage of work time missed due to hepatitis C) 
hardly changed between baseline (2.2%±7.9%, n=13) and the 
EOT (2.2%±4.4%, n=9), with a difference of 0.0%±9.0% between 
these two time points. Finally, total work productivity impair-
ment decreased very slightly (by 2.6%±40.0%) between baseline 
(25.1%±30.3%, n=13) and the EOT (22.5%±26.1%, n=9). Impor-
tantly, patients noted increased impairment in all three aspects 
of work productivity after treatment initiation (week 4) (Table 3), 
but this largely stabilized or even started to improve at week 12, 
with scores recovering–at least to some extent–at the EOT (Table 
3, Fig. 5). When only data from patients with available informa-
tion at both time points were analyzed, the temporal patterns 
of responses were similar for presenteeism and absenteeism, 
although patients actually reported a decrease (by 3.0%±7.29%, 
n=6) in the degree of absenteeism at the EOT compared with 
baseline (data not shown). In terms of total work productivity 
impairment, however, the pattern was slightly different than 
when all available data were used, in that the increased im-
pairment of baseline productivity observed at weeks 4 and 12 
persisted almost unchanged at the EOT, suggesting that some 
patients may be prone to experiencing sustained adverse effects 
associated with treatment (data not shown). It is worth noting 
that the results related to work productivity should be interpret-
ed with caution, as they arise from a limited number of patients.
The final aspect of impairment measured using WPAI was 
total activity impairment, that is, the percentage of general 
(non-work) impairment due to hepatitis. Thirty-two out of 33 
patients participating in the study provided baseline data for 
this measure, with an average total activity impairment of 
24.7%±26.0%. At the EOT, average total activity impairment 
was 37.8%±30.3% among 23 patients, which corresponded to a 
13.1%±39.9% increase in impairment from baseline, suggesting 
a deterioration of the ability to perform daily activities (Fig. 5). 
A similarly high degree of impairment was observed at week 48 
in the four patients who continued treatment until that point 
(40.0%±31.6%). Impairment in general activity followed a simi-
lar temporal pattern to that seen with work-related impairment, 
with baseline impairment worsening once IFN-based treatment 
was initiated (week 4), a further increase in impairment at week 
12, and then a decline towards the EOT (Table 3). A similar pat-
tern was observed when only patients with available data for 
both time points contributed to the analysis (data not shown).
DISCUSSION
Probably the most crucial result observed in Korean patients 
with a HCV infection initiating IFN-based treatment was a clear 
trend for decreased QoL and productivity following treatment 
initiation. Although the QoL and productivity estimates slowly 
improved over a longer treatment period, they often did so in-
completely. 
A systematic review and pooled analysis of data on QoL of 
HCV patients identified 15 studies comparing HRQoL between 
HCV patients and healthy controls.4 These studies used the SF-
36 Health Survey rather than the EQ-5D, so the data cannot be 
compared directly with our results; however, HCV was shown 
Table 3. WPAI Scores at the Consecutive Study Visits
Measure Baseline 4 Weeks 12 Weeks EOT 48 Weeks*
Absenteeism, % 2.2±7.9 (n=13) 12.9±22.2 (n=11) 6.1±13.0 (n=10) 2.2±4.4 (n=9)   0.0 (n=1)
Presenteeism, % 22.1±29.4 (n=14) 38.3±27.2 (n=12) 40.0±28.3 (n=10) 26.0±28.4 (n=10) 60.0 (n=1)
Total work productivity impairment, % 25.1±30.3 (n=13) 44.1±32.8 (n=11) 44.1±28.2 (n=10) 22.5±26.1 (n=9) 60.0 (n=1)
Total activity impairment, % 24.7±26.0 (n=32) 37.1±31.1 (n=31) 46.3±29.6 (n=27) 37.8±30.3 (n=23) 40.0±31.6  (n=4)
Data are presented as mean±SD.
WPAI, Work Productivity and Activity Impairment questionnaire; EOT, end of treatment.
*Only a single patient who continued treatment until week 48 was included. Consequently, the values for absenteeism, presenteeism and total 
work productivity impairment at week 48 are those reported by that patient.
Fig. 5. WPAI scores at baseline and at end of treatment (EOT).
WPAI, Work Productivity and Activity Impairment questionnaire.
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to have a moderate to large adverse impact on all QoL aspects 
measured, especially social and physical function, general 
health, and vitality.4 Some of that QoL impairment is likely to 
be due to the disease itself, and can be seen before treatment 
initiation. Indeed, analysis of data from 324 patients receiving 
IFN for hepatitis C relapse in an international study revealed 
that, compared with the U.S. general population, chronic hepa-
titis C patients experienced impairments in five out of eight QoL 
aspects even before treatment was initiated,3 suggesting that the 
disease itself poses a burden on the patients, adversely affecting 
their QoL. Similar results were seen among 642 North American 
patients in a multicenter, double-blind, controlled clinical trial 
of IFN, where pretreatment QoL of chronic hepatitis C patients 
was worse than that of the U.S. general population in terms of 
all eight QoL aspects studied.2 Similarly, in our study, pretreat-
ment (baseline) EQ-5D-5L score (0.87±0.103) was somewhat 
lower compared with Korean population norm (mean±standard 
error: 0.958±0.002).16 It is, however, worth noting that the gen-
eral population score quoted above was obtained using the EQ-
5D-3L questionnaire,16 and no population norm is available for 
EQ-5D-5L in Korea.
The baseline EQ-5D-VAS score (78±13.5) was almost the 
same as the Korean population norm (mean±standard error: 
79.5±0.4).16 However, the normative data are based on a 2009 
study16 and a more recent publication with a similar sample size 
reported an average EQ-5D-VAS score of 83±10 for a Korean 
general population administered the EQ-5D-5L.17 Compared 
with the latter general population score,17 HCV patients in our 
study noted a 5-point impairment in perceived health state be-
fore starting their treatment.
In addition to the impairment in general QoL, patients also 
reported impairments in work and general productivity at base-
line. Although they tended not to be absent from work due to 
hepatitis, perceived impairment while working (presenteeism), 
overall work impairment and impairment of non-work activi-
ties reached, on average, approximately 25% before the start of 
treatment.
IFN-based treatment of chronic hepatitis C has further adverse 
impact on patients’ QoL. Evidence from the aforementioned 
international study of relapsed hepatitis C patients pointed to a 
decline in patient QoL during IFN-based treatment, especially 
at the start of treatment, with some improvement seen already 
at 24 weeks of treatment and the scores returning to baseline 
over 24 weeks posttreatment.3 A similar pattern was observed 
in our study, although we did not investigate posttreatment 
values. This improvement in QoL with continued treatment sug-
gests patients may have developed a coping mechanism, and 
become somewhat used to the adverse effects of IFN and RBV. 
Alternatively, it is possible that patients who particularly poorly 
tolerated treatment discontinued it early, contributing to the 
high discontinuation rate observed. Thus, these patients–whose 
scores could be expected to be lower compared with patients 
who tolerated treatment well–would not contribute to the aver-
age QoL and productivity scores at later time points, resulting 
in improvements in scores over time. Importantly, the decline in 
HRQoL during treatment in our study was evident despite nearly 
80% of patients receiving peg-IFN, which has been shown to 
produce less QoL impairment in hepatitis C patients compared 
with standard IFN.18,19 However, the fact that all patients but one 
received RBV likely contributed to the QoL impairment, as the 
addition of RBV to IFN has been shown to reduce QoL.18
The improvement in QoL scores towards the EOT may also 
be associated with virological response, as viral RNA was un-
detectable in 23 patients (68.7%) at 48 weeks or EOT and in 22 
patients (66.7%) at ≥12 weeks posttreatment. In a number of 
studies, good virological response to treatment has been shown 
to associate with improvements in QoL compared with non-
responders.2-4,18,19 Although the attainment of good virological 
response could have contributed to the improvements in QoL 
seen over time in our study, we are unable to determine this due 
to the large amount of missing virological response data during 
the treatment period, ranging from five patients (15.2%) at week 
48 or EOT to as many as 28 (84.8%) at week 24 and 32 (97.0%) 
at week 36. Nonetheless, the fact that EQ-5D VAS results were 
similar in patients who achieved SVR12 and the overall study 
population suggests that on-treatment HRQoL is far more 
strongly affected by adverse effect of the treatment than its out-
come.
A high number of patients (n=14, 42.4%) in our study with-
drew prematurely. A pooled analysis of data from 1,441 patients 
enrolled in three international, multicenter randomized clinical 
trials of IFN reported a lower withdrawal rate, with only 10% 
of patients discontinuing treatment before week 24, but showed 
that worsening fatigue and deteriorating QoL significantly 
predicted premature discontinuation.19 With the World Health 
Organization reporting only half of chronic disease patients in 
the developed countries adhere to their medication,20 adherence 
can be seen as an issue common to many chronic diseases. In 
chronic hepatitis C, however, novel DAAs with minimal adverse 
events may improve patient adherence to therapy, providing 
hopes for better response to treatment.
MOSAIC was a non-interventional, real-world study, captur-
ing everyday clinical practice related to HCV treatment in South 
Korea. As such, it examined routine care, making the results 
more readily applicable to standard treatment of HCV patients 
seen in the clinic outside the trial setting. Undoubtedly, com-
prehensive and thorough QoL assessment is one of the greatest 
strengths of the MOSAIC study. We used validated instruments 
to assess health state and general HRQoL (EQ-5D), and HCV-
specific QoL aspects (HCV-PRO). Further, we investigated the 
impact of treatment on daily life and productivity using WPAI–
also a well-validated instrument. However, the study is not 
without limitations: the small population of treated patients 
(phases 2 and 3) combined with a high withdrawal rate means 
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many patients did not complete their treatment as planned. The 
results from week 48 arise from a particularly small number 
of patients. Although 48 weeks was the intended treatment 
duration for just over a third of the study patients, the small 
population size compounded by a high withdrawal rate meant 
only five patients completed 48 weeks of treatment. The small 
population size also particularly impacted work-related produc-
tivity measures, as these were only applicable to patients who 
were employed, that is, less than 50% of the study population 
at baseline. Another important limitation relates to the fact that 
information on doses of IFN, peg-IFN and RBV administered to 
each patient was not collected in this study. It is therefore pos-
sible that the HRQoL improvement observed towards the EOT 
could be attributed to adjustment of treatment doses. However, 
the focus of this study was on the longitudinal QoL change dur-
ing and after treatment, rather than on dose–QoL relationship. 
Hence, the results of MOSAIC, like those of any observational 
study, should be interpreted to imply association and not cau-
sality.
Following treatment initiation, the Korean cohort of IFN-
treated patients with chronic hepatitis C enrolled in the MOSAIC 
study experienced some deterioration of both general and HCV-
related HRQoL, accompanied by impairment of daily activities 
and most work productivity measures. However, towards the 
end of treatment most QoL and productivity scores improved 
markedly, often nearing pretreatment values. The QoL impair-
ment seen upon treatment initiation likely contributed to the 
high treatment discontinuation rate observed. New DAAs de-
veloped to target chronic hepatitis C should address this issue, 
aiming for HRQoL and productivity improvement in treated 
patients, which could improve adherence, ultimately improving 
patients’ chances of recovery.
CONFLICTS OF INTEREST
S.H.A. has served as an advisor and lecturer for Bristol-Myers 
Squibb, Gilead Sciences, F. Hoffmann-La Roche, Merck, AbbVie, 
and has received unrestricted grants from Bristol-Myers Squibb, 
Gilead Sciences, and F. Hoffmann-La Roche for investigator-
initiated trials. J.H. has received a grant from GSK, and research 
support from BMS and Roche; also acted as an advisor to Ab-
bvie, BMS, Gilead Sciences, Pharma Essentia, SillaJen, and 
Johnson & Johnson. D.L.S. and J.K. are employees of AbbVie, 
Inc. and may hold stock or stock options. S.W.P. has received 
grant and research support from AbbVie, BMS, Gilead, GSK, 
Merck, Novartis, and Roche. W.H.C. and Y.J.K have no conflicts 
of interest to declare.
ACKNOWLEDGMENTS 
The design, conduct, analysis, and financial sponsorship of 
the MOSAIC study were provided by AbbVie. AbbVie partici-
pated in the interpretation of data, review and approval of the 
content of this manuscript. Medical writing support was provid-
ed by Proper Medical Writing Sp. z o.o. and funded by AbbVie.
AUTHOR CONTRIBUTIONS
Study concept and design: all authors. Data acquisition: 
S.H.A., W.H.C., Y.J.K., J.H., S.W.P. Data analysis and interpreta-
tion: all authors. Drafting of the manuscript: D.L.S., J.K. Critical 
revision of the manuscript for important intellectual content: all 
authors. Statistical analysis: D.L.S., J.K. Administrative, techni-
cal, or material support; study supervision: D.L.S., J.K.
ORCID
Sang Hoon Ahn https://orcid.org/0000-0002-3629-4624
Won Hyeok Choe https://orcid.org/0000-0002-8019-5412
Yoon Jun Kim https://orcid.org/0000-0001-9141-7773
Jeong Heo https://orcid.org/0000-0003-0961-7851 
Jiho Kang https://orcid.org/0000-0002-8208-2243 
Seung Woon Paik https://orcid.org/0000-0002-6746-6652
REFERENCES
1. Sebastiani G, Gkouvatsos K, Pantopoulos K. Chronic hepatitis C 
and liver fibrosis. World J Gastroenterol 2014;20:11033-11053. 
2. Bonkovsky HL, Woolley JM. Reduction of health-related quality 
of life in chronic hepatitis C and improvement with interferon 
therapy. The Consensus Interferon Study Group. Hepatology 
1999;29:264-270. 
3. Ware JE Jr, Bayliss MS, Mannocchia M, Davis GL. Health-related 
quality of life in chronic hepatitis C: impact of disease and treat-
ment response. The Interventional Therapy Group. Hepatology 
1999;30:550-555.
4. Spiegel BM, Younossi ZM, Hays RD, Revicki D, Robbins S, Kanwal 
F. Impact of hepatitis C on health related quality of life: a system-
atic review and quantitative assessment. Hepatology 2005;41:790-
800.
5. World Health Organization (WHO). Hepatitis C: fact sheet [Internet]. 
Geneva: WHO; c2010 [cited 2017 Nov 5]. Available from: http://
www.who.int/mediacentre/factsheets/fs164/en/.
6. Petruzziello A, Marigliano S, Loquercio G, Cozzolino A, Cac-
ciapuoti C. Global epidemiology of hepatitis C virus infection: 
an up-date of the distribution and circulation of hepatitis C virus 
genotypes. World J Gastroenterol 2016;22:7824-7840.
7. Bennett H, Waser N, Johnston K, et al. A review of the burden of 
hepatitis C virus infection in China, Japan, South Korea and Tai-
wan. Hepatol Int 2015;9:378-390.
8. Kwon GY, Lee H, Gwack J, Lee SW, Ki M, Youn SK. Regional 
distribution of hepatitis C virus infection in the Republic of Korea, 
2007-2011. Gut Liver 2014;8:428-432.
9. Kim do Y, Yoon KT, Kim W, et al. Estimation of direct medical 
376  Gut and Liver, Vol. 14, No.3, May 2020
cost related to the management of chronic hepatitis C and its com-
plications in South Korea. Medicine (Baltimore) 2016;95:e3896.
10. Korean Association for the Study of the Liver. KASL clinical 
practice guidelines: management of hepatitis C. Clin Mol Hepatol 
2016;22:76-139.
11. Korean Association for the Study of the Liver (KASL). KASL 
clinical practice guidelines: management of hepatitis C. Clin Mol 
Hepatol 2014;20:89-136.
12. Herdman M, Gudex C, Lloyd A, et al. Development and prelimi-
nary testing of the new five-level version of EQ-5D (EQ-5D-5L). 
Qual Life Res 2011;20:1727-1736.
13. Janssen MF, Pickard AS, Golicki D, et al. Measurement properties 
of the EQ-5D-5L compared to the EQ-5D-3L across eight patient 
groups: a multi-country study. Qual Life Res 2013;22:1717-1727.
14. Anderson RT, Baran RW, Dietz B, Kallwitz E, Erickson P, Revicki 
DA. Development and initial psychometric evaluation of the hepa-
titis C virus-patient-reported outcomes (HCV-PRO) instrument. 
Qual Life Res 2014;23:561-570.
15. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibil-
ity of a Work Productivity and Activity Impairment instrument. 
Pharmacoeconomics 1993;4:353-365.
16. Szende A, Janssen B, Cabases J. Self-reported population health: 
an international perspective based on EQ-5D. Dordrecht: Springer, 
2014.
17. Kim SH, Ahn J, Ock M, et al. The EQ-5D-5L valuation study in 
Korea. Qual Life Res 2016;25:1845-1852.
18. Hassanein T, Cooksley G, Sulkowski M, et al. The impact of pegin-
terferon alfa-2a plus ribavirin combination therapy on health-re-
lated quality of life in chronic hepatitis C. J Hepatol 2004;40:675-
681.
19. Bernstein D, Kleinman L, Barker CM, Revicki DA, Green J. Rela-
tionship of health-related quality of life to treatment adherence 
and sustained response in chronic hepatitis C patients. Hepatology 
2002;35:704-708.
20. Sabaté E. Adherence to long-term therapies: evidence for action. 
Geneva: World Health Organization, 2003. 
